Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0359920120310030163
Korean Journal of Nephrology
2012 Volume.31 No. 3 p.163 ~ p.169
Use of low-dose sulodexide in IgA nephropathy patients on renin?angiotensin system blockades
Yang Byeong-Yun

Lee Hee-Seon
Song Sang-Heon
Kwak Ihm-Soo
Lee Soo-Bong
Lee Dong-Won
Seong Eun-Young
Abstract
Background: Despite using renin?angiotensin system (RAS) blockades, some of the patients with immunoglobulin A (IgA) nephropathy often had persistent proteinuria of more than 500mg/d. They need to be managed further by alternative methods to halt the progression of the disease; these methods could also be applied safely over a long period of time. In this context, sulodexide has been studied for the management of diabetic nephropathy.

Methods: A retrospective review was carried out involving 20 patients with IgA nephropathy who had been taking sulodexide (50mg daily) as an add-on therapy together with an optimal dose of RAS blockades during 2008?2009. We evaluated the proteinuria reduction rates and renal function changes.

Results: During 11.1¡¾72.7 months of follow-up duration, urinary protein-to-creatinine ratio (UPCR) decreased for 1.57¡¾0.6 to 1.17¡¾0.7 g/g (P=0.032). Twenty-five percent of the patients showed a greater than 50% reduction of UPCR, and 40% had a UPCR of less than 1.0g/g at their final observations. The analysis of the factors contributing to the effect found that a higher pretreatment UPCR showed a significant correlation with the UPCR decrease (r=0.45, P=0.047). Neither the adverse effects nor the renal function impairments were documented during the management.

Conclusion: Low-dose sulodexide has an additional modest antiproteinuric effect on IgA nephropathy undergoing RAS blockade therapy.
KEYWORD
IgA nephropathy, Proteinuria, Sulodexide
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø